about
Cytotoxic and targeted therapy for hereditary cancersInnovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.Trabectedin in soft tissue sarcomas.Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?Pathology, imaging, and treatment of cardiac tumours.Introduction: 1 year of silence?Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.Long-Lasting Response to Trabectedin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report.
P2860
Q26739366-56BDED51-2894-4B10-89EC-996F81427DBDQ37644536-EFA03D49-CF14-443D-A901-DF4DCD11C44AQ38232370-99F8D8DE-8D7F-4BE3-AF90-CBC0A8AF62F6Q38963228-3D076178-841F-447F-B4F4-FD014981403FQ39258337-AD5BCBE4-4D18-416F-8BDF-AE44E0CF9B1AQ45803008-F877E857-F3FC-465D-9D9B-8E4F027A8C5EQ52603413-0B39460D-DB3D-4E06-90B8-55489FA9822FQ52668427-72E0456A-43A7-4116-BF38-217E8D827139
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Trabectedin mechanism of action: what's new?
@en
type
label
Trabectedin mechanism of action: what's new?
@en
prefLabel
Trabectedin mechanism of action: what's new?
@en
P2860
P356
P1433
P1476
Trabectedin mechanism of action: what's new?
@en
P2093
Maurizio D'Incalci
P2860
P356
10.2217/FON.13.207
P407
P433
P577
2013-12-01T00:00:00Z